Team

Kolin C. Hribar, PhD, founded Cypre on the premise that cancer drug discovery and development needed more human-translatable models to predict therapeutic outcomes before the clinic. With his bioengineering background from UC San Diego and the University of Pennsylvania and Cypre’s exceptional team of engineers and scientists, the company established early relationships with top pharmaceuticals like Genentech and commercialized its platform through the premier CRO, Charles River. Cypre now works with many of the leading biotechnology and pharmaceutical companies around the world.